Darcy Lewis | Authors


RET, MET Inhibitors Advance Targeted Therapies in NSCLC

December 28, 2020

FDA approvals of novel agents for molecularly defined subtypes of non–small cell lung cancer are poised to change both patient outcomes as well as pretreatment testing requirements for those harboring these tumors.

Conditioning with Thiotepa-busulfan-fludarabine Improves Outcomes for Patients with MF Undergoing ASCT

December 28, 2020

When patients with myelofibrosis who required hematopoietic stem cell transplant received a conditioning regimen of thiotepa, busulfan, and fludarabine along with 2 two alkylating agents, the subsequent transplants were nearly all successful.

A Long-Term Survival Picture Emerges as Follow-up Data From NSCLC Trials Mature

November 16, 2020

Dramatic improvements in efficacy outcomes for patients with non–small cell lung cancer have been a reason for celebration over the last decade, as FDA approvals of immunotherapy-plus-chemotherapy combinations as well as oncogenic-targeting drugs have transformed the treatment landscape.

Meta-Analysis Highlights Commonly Mutated Genes in Mantle Cell Lymphoma

August 17, 2020

The frequency of mutations in patients with mantle cell lymphoma has a tendency to increase at clinical turning points like disease relapse and progression compared with at the time of diagnosis, according to a systemic review and meta-analysis.